Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer
- DOI
- 10.1093/annonc/mdw607
- Published
- 2017-02
- Container
- Annals of Oncology
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1093/annonc/mdw607,
title = {Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer},
author = {T.R.J. Evans and E. Van Cutsem and M.J. Moore and I.S. Bazin and A. Rosemurgy and G. Bodoky and G. Deplanque and M. Harrison and B. Melichar and D. Pezet and A. Elekes and E. Rock and C. Lin and L. Strauss and P.J. O’Dwyer},
year = {2017},
journal = {Annals of Oncology},
doi = {10.1093/annonc/mdw607},
url = {https://doi.org/10.1093/annonc/mdw607}
}RIS
TY - JOUR TI - Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer AU - T.R.J. Evans AU - E. Van Cutsem AU - M.J. Moore AU - I.S. Bazin AU - A. Rosemurgy AU - G. Bodoky AU - G. Deplanque AU - M. Harrison AU - B. Melichar AU - D. Pezet AU - A. Elekes AU - E. Rock AU - C. Lin AU - L. Strauss AU - P.J. O’Dwyer PY - 2017 JO - Annals of Oncology DO - 10.1093/annonc/mdw607 UR - https://doi.org/10.1093/annonc/mdw607 ER -
APA
Evans, T., Cutsem, E. V., Moore, M., Bazin, I., Rosemurgy, A., Bodoky, G., Deplanque, G., Harrison, M., Melichar, B., Pezet, D., Elekes, A., Rock, E., Lin, C., Strauss, L., & O’Dwyer, P. (2017). Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer. Annals of Oncology. https://doi.org/10.1093/annonc/mdw607
Source records
- crossref · retrieved 2026-09-27T08:50:46.068Z